Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

June 2026 Updated Prior Authorization Criteria for Tezepelumab-Ekko (Tezspire) Procedure Code J2356

Last updated on

Effective for dates of service on or after June 1, 2026, the Texas Medicaid & Healthcare Partnership (TMHP) may consider prior authorization for tezepelumab-ekko (Tezspire), procedure code J2356, as an add-on maintenance treatment for adult and pediatric clients who are 12 years of age or older and have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.